Our team of experts brings together over 20 years of excellence in clinical research and operations. TDDA’s partnerships with innovative biopharmaceutical companies has led to the advancement of scientific knowledge and the delivery of better treatment options for patients. For this reason, we are a proven leader in the in the global research community.

TDDA specializes in the following areas of research:

GI

Gastroenterology

270,000 Canadians are living with inflammatory bowel disease (IBD). By 2030, the number of Canadians with IBD is expected to rise to 400,000 (approximately 1% of the population). TDDA has extensive experience in conducting IBD research related to Crohn’s and Ulcerative Colitis, working with leading Canadian KOLs to advance treatment options.
Hep

Hepatology

Liver cirrhosis is most commonly caused by alcohol, hepatitis B, hepatitis C, and non-alcoholic fatty liver disease. Non-alcoholic fatty liver disease is the most common liver disease in Canada, affecting over 7 million people.
Derm

Dermatology

New therapies in development for the immunomodulation of common immunological skin diseases include biologicals aimed at neutralizing TNF-alfa and chemokine receptor inhibitors.
Infection White

Infectious Disease

Infectious diseases are caused by pathogenic microorganisms, such as bacteria, viruses, parasites or fungi. Therapeutic development includes research focused on Hepatitis B/C, C. difficile, H.pylori and Coronaviruses.
Asset 19

Urology

The most common clinical issues relate to prostate disease and cancer, male infertility, colic, kidney stones, renal transplantation, erectile and bladder dysfunction, and urinary tract infections. The prevalence of urological disorders among males age 35 and up is consistently growing, with more than half of men between the ages of 40 and 88 afflicted by ED.
Asset 20

Respirology

It has been estimated that more than 3 million Canadians live with serious respiratory diseases: asthma, chronic obstructive pulmonary disease, lung cancer, tuberculosis and cystic fibrosis. Respiratory diseases affect people all ages and most are chronic in nature, not only having a major impact on the individual but on families, communities, and the health care system.
Asset 18

cardiology

In Canada, heart disease is the second leading cause of death and the primary reason for hospitalization. Approximately 2.4 million Canadian adults live with diagnosed heart disease, meanwhile every hour ~12 Canadians diagnosed with heart disease die.
Asset 17

immunology

Immunology research encompasses both the discovery of fundamental mechanisms underlying healthy and unhealthy immune responses, as well as the application of this knowledge to improve prevention and treatment of disease.
Asset 24

rheumatology

Rheumatology is a branch of medicine devoted to the diagnosis and therapy of, often progressive, rheumatic diseases such as arthritis, other diseases of the joints, tendons, muscles, and bones. Arthritis, in particular, is a leading cause of pain, physical disability and health care utilization in Canada. By the year 2026, it is estimated that over 6 million Canadians 15 years of age and older will have arthritis. The need to understand the tremendous burden of arthritis on both individuals and society as a whole is urgent.

Scientific Leaders

TDDA collaborates with a growing network of scientific Key Opinion Leaders (KOLs) to broaden our depth of therapeutic knowledge and expertise in trial delivery.

DR. JORDAN FELD, M.D.

Hepatology

DR. HARRY JANSSEN, M.D.

Hepatology

DR. HEMANT SHAH, M.D.

Hepatology

DR. MILAN PATEL, M.D.

Respirology

DR. REMO PANACCIONE, M.D.

IBD

DR. ROBERT BAILEY, M.D.

IBD

DR. SANJAY SIDDHA, M.D.

Dermatology

DR. AMISH PARIKH, M.D.

Endocrinology

DR. CURTIS COOPER, M.D.

Infectious Disease

DR. ZACHARY KLINGHOFFER, M.D.

Urology

DR. ANIL GUPTA, M.D.

Cardiology

Asset 3@300x

company

Help